VKTX insider trading
NasdaqCM HealthcareViking Therapeutics, Inc. — scored insider trade history from SEC Form 4 filings, parsed and contextualised by FilingIQ.
About Viking Therapeutics, Inc.
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. Its lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. The company develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, which is in Phase II clinical trials for metabolic disorders and anemia; VK2735, a novel dual agonist of the glucagon-like peptide 1, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.
Company website: www.vikingtherapeutics.com
VKTX insider activity at a glance
FilingIQ has scored 336 insider transactions for VKTX since Apr 28, 2015. The most recent filing in our index is dated Mar 10, 2026.
Across the full history, 10 open-market purchases
and 105 open-market sales
were filed under transaction codes P and S respectively. Compensatory share awards
(code A) and option exercises (code M) are tracked separately and not counted here.
The average FilingIQ composite score on VKTX insider trades is 65.0/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.
Latest VKTX Form 4 filings
Most recent disclosures. Sign up to filter by score, transaction code, or insider role.
Other Healthcare tickers with recent insider activity
13F funds holding VKTX
Frequently asked
- How many insider trades does FilingIQ track for VKTX?
- FilingIQ tracks 336 Form 4 insider transactions for VKTX (Viking Therapeutics, Inc.), covering filings from Apr 28, 2015 onwards. 1 of those were filed in the last 90 days.
- Are VKTX insiders net buyers or net sellers?
- Across the full Form 4 history for VKTX, 10 transactions (3%) were open-market purchases and 105 (31%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
- Where does VKTX insider data come from?
- Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.
- What sector is VKTX in?
- Viking Therapeutics, Inc. (VKTX) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $3.92B.
Methodology & sources
Every VKTX insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.